Evidence map›Paper›PMID 41050130›Full record

ArticleKidney medicine2025

Acute-Onset Posttransplant Lymphoproliferative Disorder After Kidney Transplant.

Ismael Z Assi, Shalini Bumb, Shikha Jaiswal, Michelle M Bryant, Silvi Shah

Abstract readCase Reports
In one paragraph

Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ismael Z AssiUniversity of Cincinnati College of Medicine, Cincinnati, OH.
Shalini BumbDivision of Nephrology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.
Shikha JaiswalDivision of Nephrology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.
Michelle M BryantDepartment of Pathology & Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.
Silvi ShahDivision of Nephrology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Posttransplant lymphoproliferative disorder (PTLD) encompasses a spectrum of potentially life-threatening lymphoid proliferations that can arise after solid-organ transplantation, with a bimodal onset typically occurring approximately 12-14 months or approximately 4 years after transplant. Here, we present a novel case of a patient who developed PTLD with an unusually rapid onset, occurring just 7 weeks after receiving a deceased donor kidney transplant. The patient, an Epstein-Barr virus (EBV)-negative recipient of an EBV-positive donor kidney with a complete human leukocyte antigen mismatch, experienced early posttransplant complications including bacteremia and fungemia. These infections, in conjunction with high-risk EBV serostatus and possible underlying genetic susceptibility, may have contributed to uncontrolled B-cell proliferation in the setting of the patient's impaired immune surveillance. Kidney biopsy confirmed EBV-positive monomorphic diffuse large B-cell lymphoma. The patient was successfully treated with rituximab and reduction of immunosuppression, resulting in resolution of EBV viremia. This case underscores the need to consider PTLD even in the very early posttransplant period, especially in EBV-mismatched recipients, and highlights the complex interplay among infections, immunosuppression, and lymphoproliferative disease pathogenesis.

Indexed as

Post-transplant Lymphoproliferative Disorder, Epstein-Barr Virus, Kidney Transplant

Identifiers

PMID41050130
PMCPMC12489818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.